What question did this study set out to answer?

To evaluate the antianginal efficacy and safety of amlodipine versus placebo as adjunctive therapy in patients with stable exertional angina pectoris receiving stable maintenance doses of beta-blockers.

January 1, 1991Journal of Cardiovascular Pharmacology

A 6-Week Double-Blind Comparison of Amlodipine and Placebo in Patients with Stable Exertional Angina Pectoris Receiving Concomitant β-Blocker Therapy

View Full Paper

Ask AI

Bookmark

Why the study?

Does amlodipine improve exercise time to angina onset in patients with stable exertional angina pectoris receiving concomitant beta-blocker therapy?

Population

Patients with stable exertional angina pectoris receiving concomitant beta-blocker therapy

Comparison

Amlodipine 5 mg once daily added to constant… vs Placebo added to constant recommended…

Design

RCT, randomized, double-blind

Follow-up

6 weeks

Authors

WKW. KleinSilesian University of Technology VMVeselin MitrovićInstitute of Social Sciences HNH NeussMax Planck Institute for Heart and Lung Research

Discussion

Member takes

Implication

Supports amlodipine add-on to beta-blockers in stable angina; extends randomized evidence for combination antianginal therapy.

Key Points

To evaluate the antianginal efficacy and safety of amlodipine versus placebo as adjunctive therapy in patients with stable exertional angina pectoris receiving stable maintenance doses of beta-blockers.
Conducted a 6-week multicenter, double-blind, randomized trial comparing amlodipine (5 mg once daily, titrated to 10 mg after 2 weeks if angina persisted) against placebo in patients on constant beta-blocker therapy.
Assessed antianginal efficacy via patient diaries, investigator and patient global evaluations, and bicycle exercise testing at baseline and after 2 and 6 weeks of double-blind treatment.
Time to onset of angina during exercise increased by 13% in the amlodipine group compared to 6% with placebo (p < 0.05).
Total exercise duration improved by 11% with amlodipine versus 2% with placebo, though this difference did not achieve statistical significance.
Patients receiving amlodipine experienced reductions in both angina attack frequency and nitroglycerin consumption, with a low incidence of adverse effects and laboratory abnormalities.

Structured PICO

Does amlodipine improve exercise time to angina onset in patients with stable exertional angina pectoris receiving concomitant beta-blocker therapy?

Population

Patients with stable exertional angina pectoris receiving concomitant beta-blocker therapy

Intervention

Amlodipine 5 mg once daily (adjusted to 10 mg daily after 2 weeks if angina attacks were not abolished) added to constant recommended maintenance doses of beta-blockers for 6 weeks

Comparator

Placebo added to constant recommended maintenance doses of beta-blockers

Outcome

Exercise time to angina onset assessed with bicycle exercise testssurrogate

The addition of amlodipine to beta-blocker therapy in patients with stable angina pectoris is well tolerated and improves antianginal efficacy, specifically increasing exercise time to angina onset.

Cite This Study

Klein et al. (1991) studied this question.

synapsesocial.com/papers/6a735a9455ee283707b871fb https://doi.org/10.1097/00005344-199117001-00016

View Full Paper

Ask AI

Bookmark

A 6-Week Double-Blind Comparison of Amlodipine and Placebo in Patients with Stable Exertional Angina Pectoris Receiving Concomitant β-Blocker Therapy

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

A 6-Week Double-Blind Comparison of Amlodipine and Placebo in Patients with Stable Exertional Angina Pectoris Receiving Concomitant β-Blocker Therapy

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Also Consider

Also Consider